20/20 GeneSystems News
Home : News
|
20/20 Licenses Lung Cancer Blood Test to Ortho-Clinical Diagnostics 20/20 receives $150,000 in joint funding from Johnson & Johnson and TEDCO. BioCheck® Kit for Screening Suspicious Powders Receives SAFETY Act Designation from DHS 20/20 wins $2M ATP award to further develop LES Technology 20/20 Announces Significant Development of Innovative Layered Peptide Array Technology 20/20 Closes $1.75 Investment Round. Company Leverages New Maryland Investor Tax Credit. 20/20 Moves into New Headquarters
20/20 Investors Seek Refund through New Maryland Biotech Investment Incentive Act 20/20 announces a report published in the Journal of Thoracic Oncology showing that its multi-biomarker blood test appears able to detect non-small cell lung cancer (NSCLC) significantly earlier and with better accuracy than existing tests.
20/20 Receives an STTR Award To Further Develop a Diagnostic Test for Early Stage Lung Cancer
Dec 29, 2005 Dec. 13, 2005 May 13, 2005 Apr 2005
|